Abbott 1-Year Results Show Portico Valve Safely Cut Severe Aortic Stenosis

One-Year Results from Real-World Study Showed Abbott’s Portico™ Transcatheter Aortic Valve Safely and Successfully Reduced Severe Aortic Stenosis

– Late-breaking data from real-world experience with the first fully repositionable and retrievable valve were consistent with previous results, and support that Portico can be successfully used in various anatomies in a real-world setting

– Patients who received a Portico aortic heart valve had low rates of stroke, death and valve leak; and improved heart failure symptoms, quality of life and functional capacity

– The minimally invasive Portico procedure allows doctors to replace a diseased or damaged aortic heart valve without major surgery

Abbott (NYSE: ABT) today announced one-year results from a real-world, international, multicenter, 941-patient study of the company’s Portico™ transcatheter aortic valve replacement (TAVR) system in patients with symptomatic, severe aortic stenosis – a life-threatening narrowing of the heart’s aortic valve. At one year, implantation with the Portico valve was safe and associated with low rates of stroke, death and leaks between patients’ natural heart tissue and the Portico valve.

The one-year results from the PORTICO I study were presented during a late-breaking session at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation in San Diego, and simultaneously published in the Journal of the American College of Cardiology. Results at one year were consistent with 30-day results reported earlier this year; with data used to support CE Mark; and with data and results from other commercially available TAVR valves. Portico is under investigation in the United States.

The Portico transcatheter valve is a minimally invasive alternative to surgical aortic valve replacement for patients diagnosed with severe aortic stenosis who are high-risk candidates for open-heart surgery. Aortic stenosis is a common and life-threatening valve disease in which the aortic valve opening in the heart narrows and restricts blood flow from the left ventricle to the aorta. More than one in eight people aged 75 and older have moderate or severe aortic stenosis,[1] which reduces the heart’s pumping ability. Most patients don’t have symptoms for decades, but once symptoms appear, the prognosis is poor without surgical treatment,[2] manifesting in shortness of breath, fatigue, and ultimately heart failure.[3]

‘Portico offers physicians the ability to safely and successfully treat patients suffering from symptomatic, severe aortic stenosis with a high level of confidence,’ said Lars Sondergaard, M.D., DMSc, Rigshospitalet, Copenhagen, Denmarkand principal investigator of the study. ‘These one-year results in a real-world setting give us assurance that Portico is an excellent and important treatment option for patients with severe aortic stenosis who are at increased risk for open-heart surgery.’

https://www.marketscreener.com/ABBOTT-LABORATORIES-11506/news/Abbott-Laboratories-One-Year-Results-from-Real-World-Study-Showed-Abbott-s-Portico-trade-Transcat-27316623/